Compare AMS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | IBIO |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 16.4M |
| IPO Year | N/A | N/A |
| Metric | AMS | IBIO |
|---|---|---|
| Price | $2.06 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 11.4K | ★ 13.2M |
| Earning Date | 11-13-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,423,000.00 | $500,000.00 |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | $11.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 17.84 | ★ 185.71 |
| 52 Week Low | $2.01 | $0.56 |
| 52 Week High | $3.39 | $6.89 |
| Indicator | AMS | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 58.11 |
| Support Level | $2.03 | $1.86 |
| Resistance Level | $2.15 | $2.13 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.75 | 36.44 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.